Abstract
Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based interventions in HRS. A number of factors can precipitate HRS. The monitoring, prevention, early detection, and correct treatment of these are essential. Terlipressin combined with albumin is the first-line treatment of type 1 HRS. In type 2 HRS with refractory ascites, liver transplantation and TIPS should be considered.
Bidragets oversatte titel | Hepatorenal syndrome: diagnosis, treatment and prevention |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 175 |
Udgave nummer | 22 |
Sider (fra-til) | 1562-6 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 27 maj 2013 |
Emneord
- Albumins
- Ascites
- Drug Therapy, Combination
- Evidence-Based Medicine
- Hepatorenal Syndrome
- Humans
- Kidney
- Liver Cirrhosis
- Liver Transplantation
- Lypressin
- Portasystemic Shunt, Transjugular Intrahepatic
- Vasoconstrictor Agents